liothyronine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| 1585 | 6893-02-3 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
A T3 thyroid hormone normally synthesized and secreted by the thyroid gland in much smaller quantities than thyroxine (T4). Most T3 is derived from peripheral monodeiodination of T4 at the 5' position of the outer ring of the iodothyronine nucleus. The hormone finally delivered and used by the tissues is mainly T3.
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
| Dose | Unit | Route |
|---|---|---|
| 60 | mcg | O |
| 60 | mcg | P |
ADMET properties:
| Property | Value | Reference |
|---|---|---|
| MRTD (Maximum Recommended Therapeutic Daily Dose) | 0.00 µM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
| BDDCS (Biopharmaceutical Drug Disposition Classification System) | 2 | Hosey CM, Chan R, Benet LZ |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| May 8, 1956 | FDA | KING PHARMS R AND D |
FDA Adverse Event Reporting System (Female)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Sensitisation | 338.27 | 14.28 | 83 | 12364 | 2285 | 56277335 |
| Polycystic ovaries | 315.32 | 14.28 | 84 | 12363 | 3230 | 56276390 |
| Ejection fraction | 275.07 | 14.28 | 66 | 12381 | 1649 | 56277971 |
| Hypothyroidism | 262.26 | 14.28 | 140 | 12307 | 38056 | 56241564 |
| Rhinitis allergic | 241.40 | 14.28 | 85 | 12362 | 8389 | 56271231 |
| Blood test abnormal | 207.40 | 14.28 | 85 | 12362 | 12699 | 56266921 |
| Carpal tunnel syndrome | 194.26 | 14.28 | 90 | 12357 | 18054 | 56261566 |
| Sleep apnoea syndrome | 191.50 | 14.28 | 100 | 12347 | 25961 | 56253659 |
| Sleep disorder due to a general medical condition | 191.46 | 14.28 | 73 | 12374 | 9017 | 56270603 |
| Burning sensation | 147.55 | 14.28 | 106 | 12341 | 48590 | 56231030 |
| Nephrectomy | 135.81 | 14.28 | 35 | 12412 | 1178 | 56278442 |
| Cardiac disorder | 132.44 | 14.28 | 97 | 12350 | 45790 | 56233830 |
| Fibromyalgia | 116.14 | 14.28 | 100 | 12347 | 59503 | 56220117 |
| Renal disorder | 114.63 | 14.28 | 75 | 12372 | 29530 | 56250090 |
| Gastrooesophageal reflux disease | 103.60 | 14.28 | 109 | 12338 | 83148 | 56196472 |
| Asthma | 95.43 | 14.28 | 121 | 12326 | 112649 | 56166971 |
| Ejection fraction abnormal | 91.08 | 14.28 | 25 | 12422 | 1075 | 56278545 |
| Loss of personal independence in daily activities | 82.98 | 14.28 | 96 | 12351 | 81273 | 56198347 |
| Therapeutic product effect incomplete | 74.64 | 14.28 | 104 | 12343 | 105927 | 56173693 |
| Headache | 53.96 | 14.28 | 255 | 12192 | 558789 | 55720831 |
| Hypertension | 48.61 | 14.28 | 141 | 12306 | 244137 | 56035483 |
| Hyperthyroidism | 42.54 | 14.28 | 30 | 12417 | 13322 | 56266298 |
| Urine chloride decreased | 39.65 | 14.28 | 8 | 12439 | 86 | 56279534 |
| Suicidal ideation | 36.71 | 14.28 | 54 | 12393 | 57688 | 56221932 |
| Wheezing | 36.41 | 14.28 | 62 | 12385 | 74964 | 56204656 |
| Urine sodium decreased | 34.97 | 14.28 | 8 | 12439 | 161 | 56279459 |
| Rheumatoid arthritis | 33.13 | 14.28 | 22 | 12425 | 382582 | 55897038 |
| Weight increased | 31.60 | 14.28 | 117 | 12330 | 229586 | 56050034 |
| Myopathy | 31.15 | 14.28 | 22 | 12425 | 9790 | 56269830 |
| Palpitations | 30.74 | 14.28 | 68 | 12379 | 99604 | 56180016 |
| Product substitution issue | 27.39 | 14.28 | 24 | 12423 | 14575 | 56265045 |
| Thyroid function test abnormal | 24.69 | 14.28 | 13 | 12434 | 3420 | 56276200 |
| Drug intolerance | 24.60 | 14.28 | 14 | 12433 | 264804 | 56014816 |
| Systemic lupus erythematosus | 24.49 | 14.28 | 5 | 12442 | 180073 | 56099547 |
| Glossodynia | 23.49 | 14.28 | 3 | 12444 | 152455 | 56127165 |
| Feeling abnormal | 22.66 | 14.28 | 73 | 12374 | 133529 | 56146091 |
| Arthropathy | 22.65 | 14.28 | 8 | 12439 | 200267 | 56079353 |
| Acute kidney injury | 21.97 | 14.28 | 13 | 12434 | 240750 | 56038870 |
| Blood thyroid stimulating hormone increased | 21.49 | 14.28 | 15 | 12432 | 6548 | 56273072 |
| Wound | 20.75 | 14.28 | 3 | 12444 | 138801 | 56140819 |
| Maternal exposure during pregnancy | 20.71 | 14.28 | 8 | 12439 | 189545 | 56090075 |
| Tri-iodothyronine increased | 20.35 | 14.28 | 5 | 12442 | 138 | 56279482 |
| Blood thyroid stimulating hormone abnormal | 18.72 | 14.28 | 7 | 12440 | 817 | 56278803 |
| Nail growth abnormal | 18.02 | 14.28 | 6 | 12441 | 499 | 56279121 |
| Thyroid cancer | 17.48 | 14.28 | 12 | 12435 | 5104 | 56274516 |
| Peak expiratory flow rate decreased | 16.87 | 14.28 | 6 | 12441 | 608 | 56279012 |
| Blood thyroid stimulating hormone decreased | 16.81 | 14.28 | 11 | 12436 | 4322 | 56275298 |
| Product quality issue | 16.42 | 14.28 | 27 | 12420 | 31709 | 56247911 |
| Thrombocytopenia | 16.17 | 14.28 | 5 | 12442 | 136219 | 56143401 |
| Death | 16.10 | 14.28 | 32 | 12415 | 341394 | 55938226 |
| Reaction to excipient | 15.72 | 14.28 | 7 | 12440 | 1277 | 56278343 |
| Pre-existing condition improved | 15.59 | 14.28 | 13 | 12434 | 7385 | 56272235 |
| Tri-iodothyronine decreased | 15.45 | 14.28 | 4 | 12443 | 137 | 56279483 |
| Product dose omission issue | 15.17 | 14.28 | 87 | 12360 | 204666 | 56074954 |
| Scar | 14.94 | 14.28 | 16 | 12431 | 12417 | 56267203 |
| Hospitalisation | 14.58 | 14.28 | 43 | 12404 | 74957 | 56204663 |
| General physical health deterioration | 14.38 | 14.28 | 10 | 12437 | 170000 | 56109620 |
FDA Adverse Event Reporting System (Male)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Performance enhancing product use | 50.50 | 23.37 | 8 | 1593 | 98 | 31695645 |
| Rhythm idioventricular | 48.95 | 23.37 | 9 | 1592 | 277 | 31695466 |
| Secondary hypogonadism | 48.73 | 23.37 | 9 | 1592 | 284 | 31695459 |
| Thyrotoxic periodic paralysis | 43.52 | 23.37 | 7 | 1594 | 95 | 31695648 |
| Autoimmune thyroiditis | 41.97 | 23.37 | 10 | 1591 | 1095 | 31694648 |
| Loose associations | 39.36 | 23.37 | 6 | 1595 | 56 | 31695687 |
| Glucose tolerance decreased | 37.91 | 23.37 | 6 | 1595 | 73 | 31695670 |
| Diffuse vasculitis | 37.61 | 23.37 | 6 | 1595 | 77 | 31695666 |
| Sinus arrest | 34.09 | 23.37 | 9 | 1592 | 1492 | 31694251 |
| Feelings of worthlessness | 30.37 | 23.37 | 6 | 1595 | 272 | 31695471 |
| Haematocrit increased | 27.51 | 23.37 | 8 | 1593 | 1889 | 31693854 |
| Pressure of speech | 27.23 | 23.37 | 6 | 1595 | 464 | 31695279 |
| Hyperthyroidism | 26.99 | 23.37 | 12 | 1589 | 9619 | 31686124 |
| Insulin-like growth factor increased | 26.41 | 23.37 | 7 | 1594 | 1178 | 31694565 |
| Blood prolactin decreased | 24.87 | 23.37 | 5 | 1596 | 248 | 31695495 |
| Systolic hypertension | 24.43 | 23.37 | 5 | 1596 | 271 | 31695472 |
FDA Adverse Event Reporting System (Geriatric)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Sensitisation | 353.84 | 15.77 | 81 | 10840 | 2392 | 70915131 |
| Polycystic ovaries | 347.01 | 15.77 | 82 | 10839 | 2790 | 70914733 |
| Ejection fraction | 286.12 | 15.77 | 64 | 10857 | 1698 | 70915825 |
| Rhinitis allergic | 251.68 | 15.77 | 82 | 10839 | 9213 | 70908310 |
| Hypothyroidism | 230.70 | 15.77 | 121 | 10800 | 45634 | 70871889 |
| Carpal tunnel syndrome | 220.48 | 15.77 | 87 | 10834 | 16970 | 70900553 |
| Blood test abnormal | 211.92 | 15.77 | 81 | 10840 | 14509 | 70903014 |
| Sleep disorder due to a general medical condition | 195.76 | 15.77 | 70 | 10851 | 10406 | 70907117 |
| Sleep apnoea syndrome | 177.74 | 15.77 | 91 | 10830 | 32622 | 70884901 |
| Fibromyalgia | 160.72 | 15.77 | 97 | 10824 | 47777 | 70869746 |
| Burning sensation | 159.36 | 15.77 | 100 | 10821 | 52770 | 70864753 |
| Nephrectomy | 134.62 | 15.77 | 35 | 10886 | 1768 | 70915755 |
| Cardiac disorder | 134.47 | 15.77 | 94 | 10827 | 59321 | 70858202 |
| Gastrooesophageal reflux disease | 123.06 | 15.77 | 106 | 10815 | 90733 | 70826790 |
| Renal disorder | 109.76 | 15.77 | 70 | 10851 | 37939 | 70879584 |
| Asthma | 95.68 | 15.77 | 105 | 10816 | 120688 | 70796835 |
| Loss of personal independence in daily activities | 91.22 | 15.77 | 87 | 10834 | 84823 | 70832700 |
| Ejection fraction abnormal | 83.87 | 15.77 | 24 | 10897 | 1739 | 70915784 |
| Therapeutic product effect incomplete | 82.68 | 15.77 | 97 | 10824 | 119785 | 70797738 |
| Hyperthyroidism | 65.54 | 15.77 | 40 | 10881 | 20051 | 70897472 |
| Headache | 61.20 | 15.77 | 212 | 10709 | 580193 | 70337330 |
| Hypertension | 57.53 | 15.77 | 135 | 10786 | 295898 | 70621625 |
| Urine chloride decreased | 41.43 | 15.77 | 8 | 10913 | 100 | 70917423 |
| Performance enhancing product use | 40.39 | 15.77 | 8 | 10913 | 115 | 70917408 |
| Wheezing | 36.99 | 15.77 | 58 | 10863 | 94112 | 70823411 |
| Secondary hypogonadism | 36.87 | 15.77 | 9 | 10912 | 351 | 70917172 |
| Thyrotoxic periodic paralysis | 35.32 | 15.77 | 7 | 10914 | 101 | 70917422 |
| Urine sodium decreased | 33.66 | 15.77 | 8 | 10913 | 278 | 70917245 |
| Rhythm idioventricular | 33.45 | 15.77 | 9 | 10912 | 519 | 70917004 |
| Loose associations | 32.39 | 15.77 | 6 | 10915 | 59 | 70917464 |
| Glucose tolerance decreased | 31.00 | 15.77 | 6 | 10915 | 76 | 70917447 |
| Tri-iodothyronine increased | 29.98 | 15.77 | 7 | 10914 | 225 | 70917298 |
| Insulin-like growth factor increased | 29.95 | 15.77 | 11 | 10910 | 1760 | 70915763 |
| Diffuse vasculitis | 28.92 | 15.77 | 6 | 10915 | 110 | 70917413 |
| Suicidal ideation | 27.51 | 15.77 | 43 | 10878 | 69553 | 70847970 |
| Blood thyroid stimulating hormone decreased | 26.24 | 15.77 | 14 | 10907 | 5440 | 70912083 |
| Myopathy | 25.72 | 15.77 | 22 | 10899 | 18590 | 70898933 |
| Weight increased | 24.08 | 15.77 | 87 | 10834 | 242244 | 70675279 |
| Thrombocytopenia | 21.88 | 15.77 | 5 | 10916 | 239105 | 70678418 |
| Autoimmune thyroiditis | 21.75 | 15.77 | 11 | 10910 | 3831 | 70913692 |
| Thyroid function test abnormal | 21.23 | 15.77 | 10 | 10911 | 2987 | 70914536 |
| Blood thyroid stimulating hormone increased | 20.53 | 15.77 | 14 | 10907 | 8465 | 70909058 |
| Feelings of worthlessness | 20.20 | 15.77 | 6 | 10915 | 495 | 70917028 |
| Palpitations | 19.82 | 15.77 | 49 | 10872 | 110704 | 70806819 |
| Feeling abnormal | 19.46 | 15.77 | 57 | 10864 | 142262 | 70775261 |
| Product dose omission issue | 18.24 | 15.77 | 74 | 10847 | 217394 | 70700129 |
| Product substitution issue | 18.03 | 15.77 | 18 | 10903 | 18495 | 70899028 |
| Sinus arrest | 17.60 | 15.77 | 9 | 10912 | 3206 | 70914317 |
| Immunoglobulins decreased | 17.47 | 15.77 | 7 | 10914 | 1417 | 70916106 |
| Product preparation error | 17.39 | 15.77 | 10 | 10911 | 4492 | 70913031 |
| Drug withdrawal syndrome | 16.98 | 15.77 | 23 | 10898 | 32692 | 70884831 |
| Acute kidney injury | 16.45 | 15.77 | 30 | 10891 | 474594 | 70442929 |
| Pyrexia | 16.42 | 15.77 | 44 | 10877 | 606908 | 70310615 |
| Nail growth abnormal | 16.30 | 15.77 | 5 | 10916 | 460 | 70917063 |
| Pressure of speech | 15.93 | 15.77 | 6 | 10915 | 1029 | 70916494 |
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | H03AA02 | SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS THYROID THERAPY THYROID PREPARATIONS Thyroid hormones |
| ATC | H03AA03 | SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS THYROID THERAPY THYROID PREPARATIONS Thyroid hormones |
| FDA CS | M0021977 | Triiodothyronine |
| FDA EPC | N0000175946 | l-Triiodothyronine |
| CHEBI has role | CHEBI:60311 | thyroid hormones |
| CHEBI has role | CHEBI:75771 | Mus musculus metabolites |
| CHEBI has role | CHEBI:77746 | Homo sapiens metabolite |
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Goiter | indication | 3716002 | DOID:12176 |
| Myxedema coma | indication | 21263006 | |
| Hypothyroidism | indication | 40930008 | DOID:1459 |
| Myxedema | indication | 43153006 | DOID:11634 |
| Congenital hypothyroidism | indication | 190268003 | DOID:0050328 |
| Simple goiter | indication | 267369002 | |
| Malignant tumor of thyroid gland | indication | 363478007 | DOID:1781 |
| T3 Suppression for Thyroid Function Test | indication | ||
| Mild Hypothyroidism | indication | ||
| Diagnostic Test for Thyroid Dysfunction | indication | ||
| Myocardial infarction | contraindication | 22298006 | DOID:5844 |
| Thyrotoxic crisis | contraindication | 29028009 | DOID:12837 |
| Hyperthyroidism | contraindication | 34486009 | DOID:7998 |
| Hypertensive disorder | contraindication | 38341003 | DOID:10763 |
| Conduction disorder of the heart | contraindication | 44808001 | |
| Disorder of cardiovascular system | contraindication | 49601007 | DOID:1287 |
| Osteoporosis | contraindication | 64859006 | DOID:11476 |
| Diabetes mellitus | contraindication | 73211009 | DOID:9351 |
| Hypopituitarism | contraindication | 74728003 | DOID:9406 |
| Angina pectoris | contraindication | 194828000 | |
| Osteopenia | contraindication | 312894000 | |
| Primary adrenocortical insufficiency | contraindication | 373662000 | |
| Disorder of coronary artery | contraindication | 414024009 |
🐶 Veterinary Drug Use
| Species | Use | Relation |
|---|---|---|
| Dogs | Hypothyroidism | Indication |
🐶 Veterinary products
| Product | Applicant | Ingredients |
|---|---|---|
| Cytobin Tablets | Zoetis Inc. | 1 |
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 2.08 | acidic |
| pKa2 | 8.12 | acidic |
| pKa3 | 8.77 | Basic |
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Thyroid hormone receptor alpha | Nuclear hormone receptor | AGONIST | Kd | 10.24 | CHEMBL | CHEMBL | |||
| Thyroid hormone receptor beta | Nuclear hormone receptor | AGONIST | Ki | 10.10 | CHEMBL | CHEMBL | |||
| Adenosine receptor A1 | GPCR | Ki | 6.62 | DRUG MATRIX | |||||
| Cytochrome P450 2C9 | Enzyme | EC50 | 6.30 | WOMBAT-PK | |||||
| Prothrombin | Enzyme | EC50 | 8.92 | CHEMBL | |||||
| Peroxisome proliferator-activated receptor gamma | Nuclear hormone receptor | Kd | 6.15 | CHEMBL | |||||
| Proliferating cell nuclear antigen | Nuclear other | IC50 | 5.44 | CHEMBL | |||||
| THAP domain-containing protein 1 | Unclassified | EC50 | 9 | WOMBAT-PK | |||||
| GABA-A receptor; anion channel | Ion channel | IC50 | 4.64 | CHEMBL | |||||
| Thyroid hormone receptor beta | Transcription factor | IC50 | 8.74 | CHEMBL | |||||
| GABA-A receptor; anion channel | Ion channel | EC50 | 5.15 | CHEMBL |
External reference:
| ID | Source |
|---|---|
| 4022167 | VUID |
| N0000020173 | NUI |
| D01011 | KEGG_DRUG |
| 55-06-1 | SECONDARY_CAS_RN |
| 4018002 | VANDF |
| 4022167 | VANDF |
| C0041014 | UMLSCUI |
| CHEBI:18258 | CHEBI |
| T3 | PDB_CHEM_ID |
| CHEMBL1544 | ChEMBL_ID |
| CHEMBL1201119 | ChEMBL_ID |
| D014284 | MESH_DESCRIPTOR_UI |
| DB00279 | DRUGBANK_ID |
| 2634 | IUPHAR_LIGAND_ID |
| 653 | INN_ID |
| 06LU7C9H1V | UNII |
| 5920 | PUBCHEM_CID |
| 10814 | RXNORM |
| 1964 | MMSL |
| 4982 | MMSL |
| d00658 | MMSL |
| 002133 | NDDF |
| 004882 | NDDF |
| 126204001 | SNOMEDCT_US |
| 350358003 | SNOMEDCT_US |
| 61275002 | SNOMEDCT_US |
Pharmaceutical products:
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| Liothyronine Sodium | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0093-2178 | TABLET | 25 ug | ORAL | ANDA | 26 sections |
| Liothyronine Sodium | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0093-2179 | TABLET | 5 ug | ORAL | ANDA | 26 sections |
| Liothyronine Sodium | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0093-2180 | TABLET | 50 ug | ORAL | ANDA | 26 sections |
| Liothyronine Sodium | HUMAN PRESCRIPTION DRUG LABEL | 1 | 16590-303 | TABLET | 50 1 | ORAL | ANDA | 13 sections |
| Liothyronine sodium | HUMAN PRESCRIPTION DRUG LABEL | 1 | 16714-166 | TABLET | 5 ug | ORAL | ANDA | 24 sections |
| Liothyronine sodium | HUMAN PRESCRIPTION DRUG LABEL | 1 | 16714-167 | TABLET | 25 ug | ORAL | ANDA | 24 sections |
| Liothyronine sodium | HUMAN PRESCRIPTION DRUG LABEL | 1 | 16714-168 | TABLET | 50 ug | ORAL | ANDA | 24 sections |
| Liothyronine Sodium | HUMAN PRESCRIPTION DRUG LABEL | 1 | 33261-964 | TABLET | 5 ug | ORAL | ANDA | 25 sections |
| Liothyronine Sodium | HUMAN PRESCRIPTION DRUG LABEL | 1 | 39822-0151 | INJECTION, SOLUTION | 10 ug | INTRAVENOUS | ANDA | 25 sections |
| Triostat | HUMAN PRESCRIPTION DRUG LABEL | 1 | 42023-120 | INJECTION | 10 ug | INTRAVENOUS | NDA | 25 sections |
| NP Thyroid 15 | HUMAN PRESCRIPTION DRUG LABEL | 2 | 42192-327 | TABLET | 2.25 ug | ORAL | unapproved drug other | 23 sections |
| NP Thyroid 15 | HUMAN PRESCRIPTION DRUG LABEL | 2 | 42192-327 | TABLET | 2.25 ug | ORAL | unapproved drug other | 23 sections |
| NP Thyroid 120 | HUMAN PRESCRIPTION DRUG LABEL | 2 | 42192-328 | TABLET | 18 ug | ORAL | unapproved drug other | 22 sections |
| NP Thyroid 120 | HUMAN PRESCRIPTION DRUG LABEL | 2 | 42192-328 | TABLET | 18 ug | ORAL | unapproved drug other | 22 sections |
| NP Thyroid 30 | HUMAN PRESCRIPTION DRUG LABEL | 2 | 42192-329 | TABLET | 4.50 ug | ORAL | unapproved drug other | 22 sections |
| NP Thyroid 30 | HUMAN PRESCRIPTION DRUG LABEL | 2 | 42192-329 | TABLET | 4.50 ug | ORAL | unapproved drug other | 22 sections |
| NP Thyroid 60 | HUMAN PRESCRIPTION DRUG LABEL | 2 | 42192-330 | TABLET | 9 ug | ORAL | unapproved drug other | 22 sections |
| NP Thyroid 60 | HUMAN PRESCRIPTION DRUG LABEL | 2 | 42192-330 | TABLET | 9 ug | ORAL | unapproved drug other | 22 sections |
| NP Thyroid 90 | HUMAN PRESCRIPTION DRUG LABEL | 2 | 42192-331 | TABLET | 13.50 ug | ORAL | unapproved drug other | 22 sections |
| NP Thyroid 90 | HUMAN PRESCRIPTION DRUG LABEL | 2 | 42192-331 | TABLET | 13.50 ug | ORAL | unapproved drug other | 22 sections |
| Liothyronine Sodium | HUMAN PRESCRIPTION DRUG LABEL | 1 | 42291-417 | TABLET | 5 ug | ORAL | ANDA | 27 sections |
| Liothyronine Sodium | HUMAN PRESCRIPTION DRUG LABEL | 1 | 42291-418 | TABLET | 25 ug | ORAL | ANDA | 27 sections |
| Liothyronine Sodium | HUMAN PRESCRIPTION DRUG LABEL | 1 | 42291-419 | TABLET | 50 ug | ORAL | ANDA | 27 sections |
| Liothyronine Sodium | HUMAN PRESCRIPTION DRUG LABEL | 1 | 42794-018 | TABLET | 5 ug | ORAL | ANDA | 27 sections |
| Liothyronine Sodium | HUMAN PRESCRIPTION DRUG LABEL | 1 | 42794-019 | TABLET | 25 ug | ORAL | ANDA | 27 sections |
| Liothyronine Sodium | HUMAN PRESCRIPTION DRUG LABEL | 1 | 42794-020 | TABLET | 50 ug | ORAL | ANDA | 27 sections |
| Liothyronine Sodium | HUMAN PRESCRIPTION DRUG LABEL | 1 | 43063-884 | TABLET | 25 ug | ORAL | ANDA | 27 sections |
| Liothyronine Sodium | HUMAN PRESCRIPTION DRUG LABEL | 1 | 43063-884 | TABLET | 25 ug | ORAL | ANDA | 27 sections |
| NP Thyroid 60 | HUMAN PRESCRIPTION DRUG LABEL | 2 | 45865-566 | TABLET | 9 ug | ORAL | unapproved drug other | 22 sections |
| Liothyronine Sodium | HUMAN PRESCRIPTION DRUG LABEL | 1 | 50090-3131 | TABLET | 5 ug | ORAL | ANDA | 27 sections |